Given that PD-L1 is upregulated by oncogenic KRAS mutations through the activation of the MEK/ERK pathway in NSCLC [105,106,107], there may be a link between EREG and PD-L1 in oncogenic KRAS-driven NSCLC. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.